Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells

Neoplasma

Volumn 62, Issue 3, 2015, Pages 432-438

  Wang, F ^a   Zhou, J ^b   Xie, X ^c   Hu, J ^c   Chen, L ^a   Hu, Q ^c   Guo, H ^c   Yu, C ^a  

^a Shaannxi Provincial People s Hospital   (China)

^b THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Cisplatin resistance apoptosis pathway; Ovarian cancer; SRPK1; UCA1

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA UCA1; MESSENGER RNA; PEPTIDES AND PROTEINS; PROTEIN BAX; PROTEIN BCL 2; SRPK1 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; OVARY CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84969664000     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_051     Document Type: Article

References (25)

1. PERMUTH-WEY J, SELLERS TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009; 472: 413-437. doi: 10. 1007/978-1-60327-492-0_20. http: //dx. doi. org/10. 10Q7/978-1-60327-492-0 20
2. HUNN J, RODRIGUEZ GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012; 55: 3-23. http: //dx. doi. org/10. 1097/GRE0b013e31824b4611
3. FLOREA AM, BUSSELBERG D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011; 3: 1351-1371. doi: cancers3011351 [pii]
4. GALLUZZI L, SENOVILLA L, VITALE I, MICHELS J, MARTINS I et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31: 1869-1883. doi: onc2011384 [pü]
5. KARTALOU M, ESSIGMANN JM. Mechanisms of resistance to cisplatin. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2001; 478: 23-43. http: //dx. doi. org/10. 1016/S0027-5107(01)00141-5
6. SHEN D-W, POULIOT LM, HALL MD, GOTTESMAN MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012; 64: 706-721. http: //dx. doi. org/10. 1124/ pr. 111. 005637
7. SIDDIK ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22: 7265-7279. http: // dx. doi. org/10. 1038/si. one. 1206933
8. MANLEY JL, TACKE R. SR proteins and splicing control. Genes Dev. 1996; 10: 1569-1579. http: //dx. doi. org/10. 1101/ gad. 10. 13. 1569
9. GRAVELEY BR. Sorting out the complexity of SR protein functions. RNA. 2000; 1197-1211.
10. SCHENK PW, BOERSMA AW, BRANDSMA JA, DEN DULK H, BURGER H et al. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res. 2001; 61: 6982-6986.
11. GOUT S, BRAMBILLA E, BOUDRIA A, DRISSI R, LAN-TUEJOUL S et al. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One. 2012; 7: e46539. http: // dx. doi. org/10. 1371/journal. pone. 0046539
12. DENG G, SUI G. Noncoding RNA in oncogenesis: A new era of identifying key players. International journal of molecular sciences. 2013; 14: 18319-18349. http: //dx. doi. org/10. 3390/ iimsl40918319
13. WANG F, LI X, XIE X, ZHAO L, CHEN W. UCAl, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS letters. 2008; 582: 1919-1927. http: //dx. doi. org/10. 1016/j. febslet. 2008. 05. 012
14. HAYES GM, CARRIGAN PE, BECK AM, MILLER LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006; 66: 3819-3827. http: //dx. doi. org/10. 1158/0008-5472. CAN-05-4Q65
15. XIE XJ, LI X, WANG F, CHEN W. [Cellular localization and tissue expression pattern of UCA1, a non-coding RNA]. Nan Fang Yi Ke Da Xue Xue Bao. 2010; 30: 57-60.
16. A LI AY, FARRAND L, KIM JY, BYUN S, SUH JY et al. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci. 2012; 1271: 58-67. http: //dx. doi. org/10. 1111/j. 1749-6632, 2012. 06734. x
17. WANG Y, CHEN W, YANG C, WU W, WU S et al. Long non-coding RNA UCAla (CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012; 41: 276.
18. CO NN, TSANG WP, TSANG TY, YEUNG CLA, YAU PL ET AL. AFlq enhancement of γ irradiation-induced apoptosis by up-regulation of BAD expression via NF-κB in human squamous carcinoma A431 cells. Oncology reports. 2010; 24: 547-554.
19. TSANG WP, WONG TW, CHEUNG AH, KWOK TT. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. Rna. 2007; 13: 890-898. http: //dx. doi. org/10. 1261/rna. 359007
20. WU W, ZHANG S, LI X, XUE M, CAO S et al. Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One. 2013; 8: e73920. doi: 10. 1371/ journal. pone. 0073920 http: //dx. doi. org/10. 1371 / iournal. pone. 0073920
21. CHIEN J, KUANG R, LANDEN C, SHRIDHAR V. Plat-inum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment. Front Oncol. 2013; 3: 251. doi: 10. 3389/fonc. 2013. 00251. http: //dx. doi. org/10. 3389/ fonc. 2013. 00251
22. FAN Y, SHEN B, TAN M, MU X, QIN Y et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014; 281: 1750-1758. doi: 10. Ill 1/febs. 12737. http: //dx. doi. org/10. 1111/febs. 12737
23. ODUNSI K, MHAWECH-FAUCEGLIA P, ANDREWS C, BECK A, AMUWO O et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PLoS One. 2012; 7: e51030. http: //dx. doi. org/10. 1371/journal. pone. 005103Q
24. SCHENK PW, STOOP H, BOKEMEYER C, MAYER F, STOT-ER G et al. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregula-tion of the protein kinase SRPK1. Neoplasia (New York, NY). 2003; 6: 297-301. http: //dx. doi. org/10. 1593/neo. 03406
25. HAYES GM, CARRIGAN PE, MILLER LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, andpancreatic carcinomas. Cancer Res. 2007; 67: 2072-2080. http: //dx. doi. org/10. 1158/0008-5472. CAN-06-2969